logo
RFK Jr claims one of his new vaccine panel members works at GW University. The school says he doesn't

RFK Jr claims one of his new vaccine panel members works at GW University. The school says he doesn't

Independent6 hours ago

Health and Human Services Secretary Robert F Kennedy Jr is facing questions after apparently misrepresenting the academic career of one of the eight people he appointed to a crucial vaccines panel.
After firing the entire 17-member line-up of the Advisory Committee on Immunization Practices (ACIP) on June 10, Kennedy named eight replacements the following day.
The secretary announced his new panelists in a post on X, along with brief biographies for each.
One of their number was Dr Michael Ross, whom Kennedy described as 'a clinical professor of obstetrics and gynecology at George Washington University and Virginia Commonwealth University, with a career spanning clinical medicine, research, and public health policy.'
However, NBC's Washington affiliate has since approached both of those universities and been informed by George Washington that Dr. Ross has not taught there for eight years and by Virginia Commonwealth that he has not worked there in four.
The network quotes another biography of the same man from the website of the private equity fund Havencrest, which makes the same claim, stating: 'A Professor of Pediatrics at George Washington University and a Professor of OB-GYN at Virginia Commonwealth University, Dr Ross serves on the boards of multiple private healthcare companies.'
The Independent has approached the Department of Health and Human Services (HHS) for clarification on the situation.
Several of Kennedy's other appointees to ACIP have also raised eyebrows due to their track record of vaccine skepticism, controversial past statements on the Covid-19 pandemic, or lack of experience.
Noel Brewer, one of the former members of the panel dismissed by Kennedy, told MSNBC recently: 'It was a bit shocking. None of us had any idea that something like this would happen.
'One of the implications of this is a bit of chaos in healthcare. It's unclear what insurance will cover and it's unclear who providers should look to when they're trying to understand what's the best practice for delivering HPV vaccine and other life-saving vaccines.'
Dr. Paul Offit, director of the Vaccine Education Center at Children's Hospital of Philadelphia, told NBC that the recent change of guard at ACIP was 'disturbing.'
'I think if you go around the table, there's a lack of expertise and experience and institutional memory,' he said. 'And what do you do now? Where do you go for information? Where do you go for advice? And I guess the answer, for right now, is go to your doctor and hope that he or she can figure it out.'
For all of the upheaval at the HHS on Kennedy's watch – which has seen huge DOGE cuts, the CDC stop recommending the Covid vaccine for healthy children and pregnant women and the secretary himself declare war on ultra-processed foods – a new poll by NBC has found that an extremely narrow majority of the American public, 51 percent, are in favor of his performance in the job.
That said, 48 percent of respondents to the survey expressed disapproval, leaving just 1 percent undecided.
Asked about the secretary's 'Make America Healthy Again' agenda, a report on which was accused of being compiled using AI, roughly one-third of people questioned said they believed junk food was the prime cause of the country's declining health, while another third blamed individuals' broader lifestyle choices.
Twelve percent blamed socioeconomic status, 10 percent cited unaffordable health insurance premiums, and six percent attributed the issue to environmental toxins.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BREAKING NEWS Famed televangelist Jimmy Swaggart fights for his life in hospital after suffering cardiac arrest
BREAKING NEWS Famed televangelist Jimmy Swaggart fights for his life in hospital after suffering cardiac arrest

Daily Mail​

timean hour ago

  • Daily Mail​

BREAKING NEWS Famed televangelist Jimmy Swaggart fights for his life in hospital after suffering cardiac arrest

Famed televangelist Jimmy Swaggart has been rushed to the hospital and remains in critical condition after suffering a terrifying cardiac arrest at his Louisiana home. The 90-year-old Grammy-nominated preacher was found unresponsive around 8am on Sunday morning, according to Swaggart Ministries. 'On this Father's Day, we urgently ask you to pray for Brother Swaggart,' Swaggart Ministries announced. 'He needs a miracle from heaven right now, this morning.' His son Donnie and grandson Gabriel reportedly rushed to his home where they took turns performing chest compressions before paramedics arrived. 'He never regained consciousness,' Donnie Swaggart said. 'We both took turns giving him chest compressions until EMT could get there.' 'I've never seen so many people arrive at one time, and I want to thank them. They were able to get a heartbeat back.' Donnie said that his condition is critical and 'without a miracle, his time will be short.' Swaggart was revived on scene and rushed to the ICU, where he remains under close observation. 'Right now, he is in ICU, and without a miracle, his time will be short. But we believe God. We're not giving up,' the family said. Swaggart is best known as the legendary leader behind the SonLife Broadcasting Network and pastor of the Family Worship Center in Baton Rouge. A towering figure in American evangelical circles, he once drew millions of viewers with his televised sermons and gospel performances. In 1981, he was nominated for a Grammy Award for Best Gospel Performance for his album Worship. His ministry was full of scandals in the late 1980s, as it was revealed the evangelist was involved with various prostitutes.

Common pregnancy complication linked to childhood seizures
Common pregnancy complication linked to childhood seizures

The Independent

time2 hours ago

  • The Independent

Common pregnancy complication linked to childhood seizures

A new study by University of Iowa Health Care researchers has found that gestational hypertension, which affects about 16 per cent of US pregnancies, is associated with an increased risk of seizures in children. The study, published in the Journal of Clinical Investigation, utilized clinical databases containing over 246 million patients and lab mice studies. Researchers found that children born to mothers with high blood pressure during pregnancy had significantly higher rates of seizures. Mice testing confirmed increased seizure sensitivity and death due to seizures in offspring exposed to gestational hypertension in the womb. The study also indicated that male offspring were more vulnerable and that brain inflammation played a significant role in the disease process, suggesting it may also do so in human children.

Second patient death reported with gene therapy for muscular dystrophy
Second patient death reported with gene therapy for muscular dystrophy

The Independent

time2 hours ago

  • The Independent

Second patient death reported with gene therapy for muscular dystrophy

Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in connection with its gene therapy for muscular dystrophy. Sarepta reported the death over the weekend and provided additional details about its response, which includes pausing shipments of the therapy, Elevidys, for older patients who are no longer able to walk. The one-time treatment is approved for children with a genetic variant of Duchenne's muscular dystrophy, which causes weakness, loss of mobility and early death in males. Elevidys is the first gene therapy approved in the U.S. for the rare muscle-wasting condition, but it has faced scrutiny since its accelerated approval in 2023. The second death, like an earlier one reported in March, occurred in a teenage boy who suffered a fatal case of acute liver injury, a known side effect of the therapy. Older patients receive a larger dose of the therapy. Sarepta said it would pause a study in those patients and assemble an expert panel to recommend new safety protocols for taking the drug. Those changes are expected to include increased use of immune-system suppressing drugs, company executives said Monday. The liver injury associated with the therapy is thought to be connected to the immune system's response. Sarepta said it was cooperating with the Food and Drug Administration, which would have to sign off on any changes to the product's use. Elevidys received expedited approval despite concerns from some FDA scientists about its effectiveness in treating Duchenne's. The FDA granted full approval last year and expanded the therapy's use to patients 4 years and older, regardless of whether they are still able to walk. Previously it was only available for younger patients who were still walking. Shares of the Cambridge, Massachusetts-based company fell more than 42% to close at about $21 in trading. Wall Street analysts speculated that FDA officials, including new vaccine chief Dr. Vinay Prasad, might impose more restrictions on the drug or even block its use. Prasad has been highly critical of the therapy since its approval under the agency's previous leadership. 'Now with two deaths reported in this segment of the market, it seems incrementally more possible that the FDA could step in and remove the therapy from the market in non-ambulatory patients,' said Leerink Partners analyst Joseph Schwartz, in a Sunday research note. Elevidys uses a disabled virus to insert a replacement gene for producing dystrophin into patient cells. It costs $3.2 million for a one-time infusion. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store